PDSB is expected to report earnings to rise 21.00% to -27 cents per share on November 12
Q3'24
Est.
$-0.28
Q2'24
Beat
by $0.10
Q1'24
Beat
by $0.07
Q4'23
Beat
by $0.09
Q3'23
Beat
by $0.10
The last earnings report on August 13 showed earnings per share of -23 cents, beating the estimate of -33 cents. With 288.38K shares outstanding, the current market capitalization sits at 140.65M.
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers